Our Pipeline

Rich and diverse

Our numbers speak volumes. With more than 130 biologics in R&D and 50 products in clinical development, we have one of the strongest, most robust pipelines in the industry.


Cardiovascular, Renal and Metabolism

Phase 1

Phase 1

  • MEDI7219 type-2 diabetes

Phase 2

Phase 2

  • MEDI0382 type-2 diabetes / obesity
  • MEDI5884 cardiovascular
  • MEDI6012 cardiovascular

Phase 3

Phase 3

LCM Projects

LCM Projects

Oncology

Phase 1

Phase 1

  • Imfinzi + Iressa non-small cell lung cancer
  • Imfinzi + MEDI0562 solid tumours
  • Imfinzi + MEDI9197 solid tumours
  • Imfinzi + adavosertib (AZD1775) solid tumours
  • Imfinzi + dabrafenib + trametinib melanoma
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + oleclumab solid tumours
  • Imfinzi + selumetinib solid tumours
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi + tremelimumab + chemotherapy 1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • Imfinzi or Imfinzi + (tremelimumab or danvatirsen (AZD9150)) diffuse large B-cell lymphoma
  • Imfinzi + RT (platform) CLOVER locally-advance head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + azacitidine myelodysplastic syndrome
  • Imfinzi + danvatirsen (AZD9150) + chemotherapy solid tumours
  • MEDI0562 solid tumours
  • MEDI1873 solid tumours
  • MEDI3726 prostate cancer
  • MEDI4276 solid tumours
  • MEDI5083 solid tumours
  • MEDI7247 haematological malignancies
  • MEDI9197 solid tumours
  • oleclumab solid tumours
  • tremelimumab + MEDI0562 solid tumours

Phase 2

Phase 2

  • Imfinzi solid tumours
  • Imfinzi + AZD5069 pancreatic ductal adenocarcinoma
  • Imfinzi + AZD5069 Imfinzi + danvatirsen (AZD9150) head and neck squamous cell carcinoma
  • Imfinzi + MEDI0680 solid tumours
  • Imfinzi + tremelimumab biliary tract, oesophageal
  • Imfinzi + tremelimumab gastric cancer
  • Imfinzi + Lynparza BAYOU 1st-line unresectable stage IV bladder cancer
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Lynparza + Imfinzi MEDIOLA solid tumors

Phase 3

Phase 3

  • Imfinzi + tremelimumab DANUBE 1st-line bladder cancer
  • Imfinzi + tremelimumab EAGLE 2nd-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab MYSTIC 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab NEPTUNE 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab + SoC CASPIAN 1st-line small cell lung cancer
  • Imfinzi + tremelimumab + chemotherapy POSEIDON 1st-line non-small cell lung cancer
  • moxetumomab pasudotox PLAIT 3rd-line hairy cell leukaemia

LCM Projects

LCM Projects

  • Imfinzi PACIFIC stage III NSCLC
  • Imfinzi PEARL (China) 1st-line non-small cell lung cancer

Respiratory

Phase 1

Phase 1

  • MEDI3506 chronic obstructive pulmonary disease

Phase 2

Phase 2

  • tezepelumab atopic dermatitis

Phase 3

Phase 3

  • Fasenra OSTRO nasal polyposis
  • Fasenra (benralizumab) CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • tezepelumab NAVIGATOR SOURCE severe, uncontrolled asthma

LCM Projects

LCM Projects

  • Fasenra TERRANOVA GALATHEA chronic obstructive pulmonary disease

Other

Phase 1

Phase 1

  • MEDI0700 systemic lupus erythematosus
  • MEDI1341 parkinson's disease
  • MEDI1814 Alzheimer’s disease
  • MEDI7352 osteoarthritis pain

Phase 2

Phase 2

  • MEDI3902 prevention of nosocomial Pseudomonas aeruginosa pneumonia
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • prezalumab primary Sjögren’s syndrome
  • suvratoxumab prevention of nosocomial Staphylococcus aureus pneumonia

Phase 3

Phase 3

  • anifrolumab TULIP systemic lupus erythematosus

LCM Projects

LCM Projects

Terminations

  • MEDI-565 solid tumours
  • mavrilimumab rheumatoid arthritis
  • inebilizumab neuromyelitis optica
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI7734 myositis
  • MEDI9314 atopic dermatitis
  • Imfinzi + tremelimumab ARCTIC 3rd-line non-small cell lung cancer


AstraZeneca Pipeline

Together with AstraZeneca, we have an exciting and balanced pipeline underpinned by great science. Uniquely positioned with both large and small molecules, the development pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.